Sanofi's Plavix withdraws from the bidding for essential drugs in Shaanxi Province (I)

Source: FDC pharmasia news 2013-7-2 Beijing - Sanofi has decided to withdraw from the bidding for essential drugs in Shaanxi Province after the price of clopidogrel, the best-selling product, has been cut by nearly 50% Given that sales of essential drugs in China are expected to continue to grow and price cuts will continue, some believe that local products may take more market share from brand generic drugs of multinational pharmaceutical companies When Plavix and other best-selling products were added to the EDL in March this year, analysts had predicted that there would be a certain price erosion After all, EDL is to make the vast population have access to drugs On March 15, China's health authorities updated EDL for the first time in four years, adding 213 new varieties, an increase of nearly 70% Many of the newly added 112 chemicals are currently commonly used cancer, cardiovascular and diabetes drugs, including Sanofi's Plavix, which ranks first in sales in China According to IMS Health, Plavix's sales in China reached 2.2 billion yuan in 2011 In addition, the new EDL also includes other patent lapsed best-selling varieties, such as Bayer AG's acarbose, Pfizer Inc.'s amlodipine and Novartis AG's valertan Now, the first batch of provincial bidding for new essential drugs has come out, and the price reduction rate still surprises many people In Shaanxi Province, located in the northwest, the price set by the local bidding department for the manufacturers is much lower than before This is especially hard for multinational pharmaceutical companies, because brand generic drugs do not enjoy any bonus points According to the new EDL drug bidding rules of Shaanxi Province, if there are more than three manufacturers bidding for the same product, the manufacturer with the lowest price will be selected If you want to enter the county-level and grass-roots hospitals in Shaanxi Province, other manufacturers must offer lower prices In order to win the bid, Sanofi has to reduce the price of 75 mg 7 Pack of Plavix from 119.1 yuan (19 US dollars) in the last bid to 65.3 yuan (10.50 US dollars), a price reduction of 45% In the face of such drastic price reduction, Sanofi decided to withdraw from the bidding; therefore, its competitor Shenzhen salubris Pharmaceutical Co Ltd won the bid successfully, with the bidding price of 25 mg 10 tablets of clopidogrel of 38.26 yuan (about $6.15), and the bidding price of 20 tablets of 74.6 yuan (about $12) 。
Similarly, Novartis's proxy has withdrawn from the Shaanxi Provincial bidding, because the price of the proxy will be reduced from 39.7 yuan (about $6.38) to 13.67 yuan (about $2.2), a 65% drop Novartis' delido (carmaxipin) won the bid, with a bid price of 27.2 yuan (about $4.37) for 30 packs Medoba, Roche's Parkinson's drug, also won the bid in Shaanxi Province, with a bid price of 82 yuan (US $13.19) for 200 mg 40 tablets.